Redeye initiates coverage of Pila Pharma, a phase II company developing a novel approach to type 2 diabetes treatment with XEN-D0501, a TRPV1 antagonist. We see little of this potential priced into the share and believe the current share price levels represent an opportunity ahead of the catalyst of the phase IIb readout.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Redeye Initiates Coverage of Pila Pharma

© Modular Finance, source Nordic Press Releases